|
Tucatinib Clinical Trials
10 actively recruiting trials across 7 locations
▼ -3 trials since June 2026
Also known as: ARRY-380, Irbinitinib, ONT-380, TUKYSA, TUKYSA, ONT-380, ARRY-380 +2 more
Pipeline
Phase 1: 2Phase 2: 5Phase 3: 1Phase 1/2: 1Phase 2/3: 1
Top Sponsors
- The Netherlands Cancer Institute1
- Seagen, a wholly owned subsidiary of Pfizer1
- SCRI Development Innovations, LLC1
- QuantumLeap Healthcare Collaborative1
- Merck Sharp & Dohme LLC1
Indications
- Cancer10
- Breast Cancer6
- HER2-positive Breast Cancer3
- HER2 Positive Rectal Adenocarcinoma1
- Locally Advanced Rectal Adenocarcinoma1
Other3 trials
Birmingham, Alabama1 trial
PRE-I-SPY Phase I/Ib Oncology Platform Program
The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center
Phase 1
Glendale, Arizona1 trial
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Palo Verde Hematology Oncology
Phase 3
Aurora, Colorado1 trial
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
University of Colorado Anschutz Medical Campus ( Site 0057)
Phase 1/2
Columbia, Maryland1 trial
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Maryland Oncology Hematology
Phase 2
Boston, Massachusetts1 trial
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2
Basking Ridge, New Jersey1 trial
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Phase 2
Houston, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.